Novavax (NVAX) October 11 Meeting Date was 'Aggressive' - FBR Says
- Wall Street falls as bank, healthcare shares weigh
- Qualcomm (QCOM) Faces U.S. Antitrust Case Over Licensing - Bloomberg
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
FBR Capital analyst Vernon Bernardino weighed in on Novavax (NASDAQ: NVAX), which is down 5% mid-day on investors concerns after the company rescheduled its annual investor meeting from next Tuesday, October 11, to Wednesday, November 9.
Bernardino said the event was highly anticipated to provide additional details on the RSV vaccine RESOLVE Phase III trial in older adults (60 years of age and older), whose topline results were announced in September 2016, and showed the pre-specified primary and secondary efficacy objectives were not met.
Bernardino commented, "We think that NVAX did the right thing in their fiduciary responsibility to disclose results early as they were material to making an investment decision. However, given the volume of data collected in RESOLVE, a study designed to support a Biologics Licensing Application (BLA), we had thought that holding the event and having detailed data ready for presentation on October 11 was aggressive. We look for a detailed analysis of biological samples to show a Phase III clinical trial with a prime boost strategy (consecutive annual vaccination) may be used to generate data that support a BLA."
The firm maintained an Outperform rating and price target of $12 onNVAX.
Shares of Novavax closed at $1.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alcobra (ADHD) PT Cut to $1.50 at Piper Jaffray as MDX P3 Misses
- Baird Cuts Price Target on GameStop (GME) Following Holiday Results
- Zendesk (ZEN) Falls as JMP Checks Suggest Q4 Bookings May Disappoint
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!